Dallas, TX: ReportsandReports announce it will carry Stakeholder Opinions: Ovarian Cancer – Approaching the era of molecular targeted therapy Market Research Report in its Store. Browse complete Stakeholder Opinions: Ovarian Cancer – Approaching the era of molecular targeted therapy Report Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ovarian cancer. The high level of unmet need, coupled with the large size of the patient population, is driving extensive R&D interest in this indication. The anticipated incorporation of molecular targeted therapies into treatment is expected to improve patient outcomes in the future. Scope Highlights Ovarian cancer is the leading cause of death from gynecological malignancies in the Western world. This is because the majority of epithelial ovarian cancer patients present with advanced disease at diagnosis, where treatment has a palliative rather than curative intent. While first-line platinum-based chemotherapy can result in high response rates of over 70-80%, the majority of patients will advanced epithelial ovarian cancer will eventually relapse with incurable disease. As such, there is a need for novel first-line therapies to improve survival rates. R&D interest in ovarian cancer is high. There are currently 85 drugs in the pipeline, which is dominated by molecular targeted therapies (42%) and cytotoxic therapies (33%). Competition for the approval of the first molecular targeted therapy in ovarian cancer is fierce. Reasons to Purchase Table Of contents Overview Catalyst 1 Summary 1 About Datamonitor healthcare 2 About the Oncology pharmaceutical analysis team 2 Executive Summary 3 Scope of the analysis 3 Datamonitor insight into the ovarian cancer market 3 Related reports 4 Upcoming reports 4 Table of Contents 5 Patient Potential 6 Key findings 6 Definition 6 Epithelial tumors 7 The vast majority of ovarian cancers are epithelial in origin 7 The majority of epithelial ovarian cancers are sporadic in nature 8 Germ cell tumors 8 Sex cord-stromal tumors 8 A successful screening test for ovarian cancer has not been developed 8 Ovarian cancer is a surgically staged malignancy 9 Epidemiology 12 The incidence of ovarian cancer in the seven major markets is forecast to reach nearly 63,000 cases by 2019 12 The highest ovarian cancer rates prevail in Northern European countries 14 Current treatment options 15 Most early-stage patients are treated with surgery and chemotherapy 15 Surgery has a central role in the management of advanced disease 16 First-line platinum-based chemotherapy is the standard of care for advanced disease 17 The use of intraperitoneal chemotherapy remains controversial 20 Maintenance therapy has not been shown to improve overall survival 21 The treatment of recurrent disease is rarely curative and depends on patients’ platinum sensitivity 22 Platinum-based combination chemotherapy is recommended for platinum-sensitive recurrent disease 23 A number of single agents can be used in the treatment of platinum-resistant recurrent disease 25 Unmet need 25 More effective agents are required for the treatment of advanced disease 25 An effective screening test could significantly improve patient survival 26 R&D efforts should be directed towards molecular targeted therapies 26 Less invasive surgical approaches should be explored for early-stage patients 27 Market potential 28 Key findings 28 Current market overview 28 Opportunities and threats 29 Opportunities 29 Significant unmet need remains in the treatment of advanced disease 29 There is increased interest in the development of molecular targeted therapies 30 There is a large patient base in ovarian cancer, and a high commercial attractiveness 30 Threats 30 The development of an effective screening modality could decrease the patient base 30 Pipeline Analysis 31 Key findings 31 Ovarian cancer pipeline overview 31 Ovarian cancer late-phase pipeline 37 Avastin (bevacizumab; Genentech/Roche/Chugai) 37 Drug profile 37 Development overview 38 Product positioning 41 SWOT analysis 42 Karenitecin (cositecan; BNP-1350; BioNumerik) 43 Drug profile 43 Development overview 44 Product positioning 46 SWOT analysis 47 Opaxio (paclitaxel poliglumex; Cell Therapeutics/Novartis) 47 Drug profile 48 Development overview 48 Product positioning 49 SWOT analysis 50 Paclical (micellar paclitaxel formulation; Oasmia) 52 Drug profile 52 Development overview 52 Product positioning 53 SWOT analysis 54 Tarceva (erlotinib; Genentech/Roche/Chugai/OSI) 55 Drug profile 55 Development overview 55 Product positioning 58 SWOT analysis 59 Vargatef (intedanib; BIBF-1120; Boehringer Ingelheim) 60 Drug profile 60 Development overview 61 Product positioning 62 SWOT analysis 63 Votrient (pazopanib; GlaxoSmithKline) 63 Drug profile 63 Development overview 64 Product positioning 67 SWOT analysis 68 Farletuzumab (MORAb-003; Morphotek/Eisai) 69 Drug profile 69 Development overview 70 Product positioning 73 SWOT analysis 74 Abagovomab (Menarini/Cell Control Biomedical) 74 Drug profile 74 Development overview 75 Product positioning 77 SWOT analysis 77 Bibliography 79 Journals 79 Websites 84 Datamonitor reports 86 Appendix Contributing experts 87 Report methodology 87 About Datamonitor 87 About Datamonitor Healthcare 87 About the Oncology analysis team 88 Disclaimer 90 Browse complete Stakeholder Opinions: Ovarian Cancer – Approaching the era of molecular targeted therapy Report Browse all Healthcare Market Research Reports Browse all Datamonitor Market Research Reports RSS Browse all Latest Report Related Reports: Stakeholder Opinions: Gastric Cancer – Targeted therapies compete for first-to-market status Commercial Insight: Molecular Targeted Cancer Therapies About Us: Contact:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapy now available at ReportsandReports
Posted by
Unknown
on
